Table 3.

Summary of epitope regions, interaction energy and interface area for selected conformation of neutralizing and therapeutic antibodies bound with SARS-CoV-2 spike protein.

Antibody	Epitope region	Length	Overlapping residues with known epitopes					Interaction energy (kcal/mol)	Interaction area (Å2)
			EPIPRED (29 residues)	7C01 (26 residues)	S2H14 (23 residues)	S2H13 (20 residues)	ACE2 (17 residues)
C002	417,449,453,455,456,473,475,484,485,486,487,488,489,490,493,494,496,498,501,505	20	11	11	14	10	14	− 17.2	855
Tremelimumab	403,406,417,449,453,455,456,484,485,486,487,488,489,493,494,495,496,498,500,501,502,505	22	8	12	17	9	15	− 15.9	848
COV2-2015	346,444,445,446,447,448,449,450,452,453,484,485,486,490,493,494,496,498,505	19	4	3	12	12	8	− 12.7	827
Afasevikumab	403,444,445,446,447,449,450,453,455,483,484,485,486,490,493,494,496,498,505	19	6	5	14	13	9	− 14.9	923
COVA2-29	403,405,406,408,409,416,417,446,447,449,453,455,493,494,496,498,500,501,502,503,504,505	22	2	12	14	6	12	− 15.6	934
Tremelimumab	403,406,417,449,453,455,456,484,485,486,487,488,489,493,494,495,496,498,500,501,502,505	22	8	12	17	9	15	− 15.9	848
HbnC3t1p1_G4	403,405,408,409,416,417,420,421,449,453,455,456,475,484,486,487,489,490,493,494,496,498,500,501,502,504,505	27	10	18	16	8	16	− 19.9	955
Ipilimumab	403,406,417,421,444,446,447,449,453,455,456,484,485,486,487,489,493,496,498,500,501,502,505	23	9	13	18	10	16	− 13.7	1039

Epitopes for neutralizing and therapeutic antibodies, which show the highest overlap with known epitope regions are highlighted.